NCT02657889 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 55
- group Id
- BG004
- value
- 122
- units
- Participants
- groups
- description
- Participants received Niraparib 200 milligrams (mg) orally once daily from Days 1 to 21 and Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.
- id
- BG000
- title
- Phase 1: Niraparib 200 mg + Pembrolizumab
- description
- Participants received Niraparib 300 mg orally once daily from Days 1 to 21 and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.
- id
- BG001
- title
- Phase 1: Niraparib 300 mg + Pembrolizumab
- description
- Participants with Ovarian Cancer (OC) received recommended phase 2 dose (RP2D) of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.
- id
- BG002
- title
- Phase 2 OC: Niraparib 200mg + Pembrolizumab
- description
- Participants with Triple Negative Breast Cancer (TNBC) received RP2D of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.
- id
- BG003
- title
- Phase 2 TNBC: Niraparib 200mg + Pembrolizumab
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 37
- group Id
- BG003
- value
- 47
- group Id
- BG004
- value
- 92
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 30
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 55
- group Id
- BG004
- value
- 122
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 7
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 50
- group Id
- BG003
- value
- 51
- group Id
- BG004
- value
- 113
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 5
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 9
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 46
- group Id
- BG003
- value
- 43
- group Id
- BG004
- value
- 103
- title
- White
- measurements
- comment
- Data on multiple race categories not collected
- group Id
- BG000
- value
- NA
- comment
- Data on multiple race categories not collected
- group Id
- BG001
- value
- NA
- comment
- Data on multiple race categories not collected
- group Id
- BG002
- value
- NA
- comment
- Data on multiple race categories not collected
- group Id
- BG003
- value
- NA
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG004
- value
- NA
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 5
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 55
- group Id
- BG004
- value
- 122
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- population Description
- The Baseline analysis Population consisted of all participants who received at least one dose of study medication.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 55
- group Id
- BG004
- value
- 122
- units
- Participants
- groups
- description
- Participants received Niraparib 200 milligrams (mg) orally once daily from Days 1 to 21 and Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.
- id
- BG000
- title
- Phase 1: Niraparib 200 mg + Pembrolizumab
- description
- Participants received Niraparib 300 mg orally once daily from Days 1 to 21 and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.
- id
- BG001
- title
- Phase 1: Niraparib 300 mg + Pembrolizumab
- description
- Participants with Ovarian Cancer (OC) received recommended phase 2 dose (RP2D) of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.
- id
- BG002
- title
- Phase 2 OC: Niraparib 200mg + Pembrolizumab
- description
- Participants with Triple Negative Breast Cancer (TNBC) received RP2D of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.
- id
- BG003
- title
- Phase 2 TNBC: Niraparib 200mg + Pembrolizumab
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 37
- group Id
- BG003
- value
- 47
- group Id
- BG004
- value
- 92
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 30
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 55
- group Id
- BG004
- value
- 122
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 7
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 50
- group Id
- BG003
- value
- 51
- group Id
- BG004
- value
- 113
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 5
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 9
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 46
- group Id
- BG003
- value
- 43
- group Id
- BG004
- value
- 103
- title
- White
- measurements
- comment
- Data on multiple race categories not collected
- group Id
- BG000
- value
- NA
- comment
- Data on multiple race categories not collected
- group Id
- BG001
- value
- NA
- comment
- Data on multiple race categories not collected
- group Id
- BG002
- value
- NA
- comment
- Data on multiple race categories not collected
- group Id
- BG003
- value
- NA
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG004
- value
- NA
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 5
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 55
- group Id
- BG004
- value
- 122
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
- population Description
- The Baseline analysis Population consisted of all participants who received at least one dose of study medication.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle